On February 27, 2019 Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, reported the Company’s VP of Business Development, Sari Fishman will participate in the Bio Asia International Conference in Tokyo, Japan on March 5th and 6th, 2019.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The BIO Asia International Conference brings together the global biotechnology and pharmaceutical industry to explore licensing collaborations and investor engagement in the current Asia-Pacific business and policy environments.

Dr. Fishman is scheduled to conduct more than 20 one-on-one meetings with business development officers from leading pharmaceutical companies interested in learning more about Can-Fite’s advanced stage drug candidates.

Can-Fite’s current pharma partnerships in Asia include distribution and development agreements with Kwang Dong in Korea for Piclidenoson, Chong Kun Dang in Korea for Namodenoson, and CMS in China for Piclidenoson and Namodenoson. The Company sees substantial additional partnership opportunities in Asia.